Posted by Michael Wonder on 18 Apr 2025
Regeneron provides update on Eylea HD (aflibercept) injection 8 mg supplemental biologics license application
18 April 2025 - Regeneron Pharmaceuticalstoday announced that the US FDA has issued a complete response letter regarding the supplemental biologics license application for the addition of extended dosing intervals (up to every 24 weeks) for EYLEA HD (aflibercept) injection 8 mg across all approved indications.
